Sprigg N, Flaherty K, Appleton JP, Salman RAS, Bereczki D, Beridze M, et al. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018;391(10135):2107-15.

Sprigg N, Robson K, Bath P, Dineen R, Roberts I, Robinson T, et al. Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial. Int J Stroke. 2016;11(6):683-94.

Flaherty K, Bath PM, Dineen R, Law Z, Scutt P, Pocock S, et al. Statistical analysis plan for the “Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage” (TICH-2) trial. Trials. 2017;18(1):17-9.

Ovesen C, Jakobsen JC, Gluud C, Steiner T, Law Z, Flaherty K, et al. Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre ‑ specified sub ‑ study of the TICH ‑ 2 trial. BMC Res Notes. 2018;11(1):379. Doi: 10.1186/s13104-018-3481-8

Winter SF, Santaguida C, Wong J, Fehlings MG. Systemic and topical use of tranexamic acid in spinal surgery: A systematic review. Glob Spine J. 2016;6(3):284-95.

McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012 Mar;72(5):585-617.

Dineen RA, Pszczolkowski S, Flaherty K, Law ZK, Morgan PS, Roberts I, et al. Does tranexamic acid lead to changes in MRI measures of brain tissue health in patients with spontaneous intracerebral haemorrhage? Protocol for a MRI substudy nested within the double-blind randomised controlled TICH-2 trial. BMJ Open. 2018;8(2):e019930.

Zehtabchi S, Abdel Baki SG, Falzon L, Nishijima DK. Tranexamic Acid for Traumatic Brain Injury: A Systematic Review and Meta-analysis. The American journal of emergency medicine. 2014;32:1503-9.